Results 41 to 50 of about 569,111 (191)

Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. [PDF]

, 2019
Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML).
Chan, Steven M, Daver, Naval G, Jonas, Brian A, Medeiros, Bruno C, Pollyea, Daniel A   +4 more
core   +1 more source

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Blood, 2009
Recently the World Health Organization (WHO), in collaboration with the European Association for Haematopathology and the Society for Hematopathology, published a revised and updated edition of the WHO Classification of Tumors of the Hematopoietic and ...
J. Vardiman, J. Thiele, D. Arber, R. Brunning, M. Borowitz, A. Porwit, N. Harris, M. L. Le Beau, E. Hellström-Lindberg, A. Tefferi, C. Bloomfield   +10 more
semanticscholar   +1 more source

Adoptive Immunotherapy in Chimeras with Donor Lymphocytes [PDF]

, 2003
Allogeneic stem cell transplantation has a well-defined indication in the treatment of hematological malignancies. The beneficial immune effect of allogeneic marrow transplantation has long been known, but only recently have methods been developed to ...
Chen, Xiao, Guenther, Wolfgang, Kolb, Hans-Jochem, Ledderose, Georg, Roskrow, Marie, Schleuning, Michael, Schmid, Christoph, Weber, Martin, Woiciechowski, Anja   +8 more
core   +1 more source

Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing

Nature, 2011
Most patients with acute myeloid leukaemia (AML) die from progressive disease after relapse, which is associated with clonal evolution at the cytogenetic level. To determine the mutational spectrum associated with relapse, we sequenced the primary tumour
L. Ding, T. Ley, D. Larson, Christopher A. Miller, D. Koboldt, J. Welch, Julie Ritchey, Margaret A. Young, T. Lamprecht, M. McLellan, Joshua F. McMichael, J. Wallis, Charles Lu, D. Shen, C. Harris, D. Dooling, R. Fulton, L. Fulton, Ken Chen, Heather K. Schmidt, Joelle M. Kalicki-Veizer, V. Magrini, L. Cook, S. McGrath, T. Vickery, M. Wendl, S. Heath, M. Watson, D. Link, M. Tomasson, W. Shannon, J. Payton, S. Kulkarni, P. Westervelt, M. Walter, T. Graubert, E. Mardis, R. Wilson, J. Dipersio   +38 more
semanticscholar   +1 more source

Recurring mutations found by sequencing an acute myeloid leukemia genome.

New England Journal of Medicine, 2009
BACKGROUND The full complement of DNA mutations that are responsible for the pathogenesis of acute myeloid leukemia (AML) is not yet known. METHODS We used massively parallel DNA sequencing to obtain a very high level of coverage (approximately 98%) of
E. Mardis, L. Ding, D. Dooling, D. Larson, M. McLellan, Ken Chen, D. Koboldt, R. Fulton, K. Delehaunty, S. McGrath, L. Fulton, Devin P. Locke, V. Magrini, R. Abbott, T. Vickery, Jerry S. Reed, J. Robinson, T. Wylie, Scott M. Smith, Lynn K. Carmichael, James M. Eldred, C. Harris, Jason R. Walker, Joshua B. Peck, Feiyu Du, Adam Dukes, Gabriel E. Sanderson, Anthony M. Brummett, Eric Clark, Joshua F. McMichael, R. Meyer, Jonathan K Schindler, C. Pohl, J. Wallis, Xiaoqi Shi, Ling Lin, Heather K. Schmidt, Yuzhu Tang, C. Haipek, Madeline E. Wiechert, Jolynda V Ivy, Joelle Kalicki, Glendoria Elliott, R. Ries, J. Payton, P. Westervelt, M. Tomasson, M. Watson, J. Baty, S. Heath, W. Shannon, R. Nagarajan, D. Link, M. Walter, T. Graubert, J. Dipersio, R. Wilson, T. Ley   +57 more
semanticscholar   +1 more source

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia [PDF]

, 2015
Approximately 20% of patients with acute myeloid leukaemia (AML) have a mutation in FMS-like-tyrosine-kinase-3 (FLT3). FLT3 is a trans-membrane receptor with a tyrosine kinase domain which, when activated, initiates a cascade of phosphorylated proteins ...
A Puissant, AJ Mohamed, BD Smith, BJ Druker, C Chung, C Dos Santos, C Thiede, C Venkataraman, CC Smith, CK Hahn, F Heidel, F Honda, G Juliusson, H Kiyoi, HS Ma, J Adolfsson, JA Dubovsky, JA Dubovsky, JA Woyach, JA Woyach, JB Petro, K Fiedler, KU Birkenkamp, L Zaitseva, M Levis, M Nakao, ML Wang, N Feldhahn, NJ Horwood, PP Zarrinkar, Q Xu, RF Schlenk, RM Stone, S Knapper, S Meshinchi, SA Ezell, SA Rushworth, SA Rushworth, SA Rushworth, SA Rushworth, T Kindler, T Matsunaga, T Oellerich, T-l Gu, V Vijayan, W Gao, Y Alvarado, Y Baba, Y Yamamoto, Y-T Tai   +49 more
core   +2 more sources

Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

Nature Communications, 2020
Clonal diversity is a consequence of cancer cell evolution driven by Darwinian selection. Precise characterization of clonal architecture is essential to understand the evolutionary history of tumor development and its association with treatment ...
Kiyomi Morita, Kiyomi Morita, Feng Wang, Katharina Jahn, Katharina Jahn, T. Hu, Tomoyuki Tanaka, Yuya Sasaki, Jack Kuipers, Jack Kuipers, S. Loghavi, Sa A. Wang, Yuanqing Yan, Ken Furudate, Ken Furudate, J. Matthews, L. Little, C. Gumbs, Jianhua Zhang, Xingzhi Song, Erika J. Thompson, K. Patel, C. Bueso-Ramos, C. Dinardo, F. Ravandi, E. Jabbour, M. Andreeff, J. Cortes, K. Bhalla, G. Garcia-Manero, H. Kantarjian, M. Konopleva, Daisuke Nakada, N. Navin, N. Beerenwinkel, N. Beerenwinkel, P. Futreal, Koichi Takahashi   +37 more
semanticscholar   +1 more source

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia [PDF]

, 2014
Bruton's tyrosine kinase (BTK) is a cytoplasmic protein found in all hematopoietic cell lineages except for T cells. BTK mediates signalling downstream of a number of receptors.
Advani, Alam, Ashino, Baba, Bendall, Billottet, Burger, Burger, Byrd, Chang, Cordle, Dasmahapatra, David J. MacEwan, de Weers, Dos Santos, Doyle, Fiedler, Gallay, Grandage, Gu, Guzman, Hahn, Herman, Herrmann, Honda, Honigberg, Horwood, Ishii, Juliusson, Kawakami, Kim, Kojima, Kristian M. Bowles, Kvinlaug, Lyubov Zaitseva, Megan Y. Murray, Min, Mohamed, Nanri, Park, Quek, Renneville, Rushworth, Rushworth, Rushworth, Shinners, Sivina, Spiekermann, Stuart A. Rushworth, Sujobert, Tai, Tamburini, Tomasson, Tsukada, Vellenga, Venkataraman, Vetrie, Welch, Westermann, Zaitseva   +59 more
core   +1 more source

Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia.

Blood, 2020
Despite recent advancements, approximately 50% of patients with acute myeloid leukemia (AML) do not respond to induction therapy (primary induction failure, PIF) or relapse after
G. Uy, Ibrahim Aldoss, M. Foster, P. Sayre, M. Wieduwilt, A. Advani, J. Godwin, M. Arellano, K. Sweet, A. Emadi, F. Ravandi, H. Erba, M. Byrne, L. Michaelis, M. Topp, N. Vey, F. Ciceri, M. Carrabba, S. Paolini, G. Huls, M. Jongen‐Lavrencic, M. Wermke, P. Chevallier, E. Gyan, C. Récher, P. Stiff, K. Pettit, B. Löwenberg, S. Church, Erica Anderson, J. Vadakekolathu, Marianne T Santaguida, M. Rettig, J. Muth, Teia Curtis, Erin Fehr, Kuo Guo, Jian Zhao, Ouiam Bakkacha, K. Jacobs, K. Tran, P. Kaminker, M. Kostova, E. Bonvini, R. Walter, J. Davidson-Moncada, S. Rutella, J. Dipersio   +47 more
semanticscholar   +1 more source

‘Acute myeloid leukemia: a comprehensive review and 2016 update'

Blood Cancer Journal, 2016
Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with an incidence of over 20 000 cases per year in the United States alone.
I. De Kouchkovsky, M. Abdul-Hay
semanticscholar   +1 more source